Get started
Author

Silvia Rita Vitale

Observed names: S. R. Vitale, SILVIA RITA VITALE, Silvia R. Vitale, Silvia Vitale, Silvia Rita Vitale, Vitale, Silvia R.
Observed institutions: Erasmus MC, University of Catania, Ferrarotto Hospital, Policlinico Universitario di Catania, Erasmus MC Cancer Institute, Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco"
ORCID: 0000-0002-7948-3580
Observed ORCID: 0000-0002-7948-3580
OpenAlex ID: A5068350069
AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?
2021 · Federica Martorana, Gianmarco Motta, et al. · Frontiers in Pharmacology · 216
PDF
Application of circulating tumor DNA in prospective clinical oncology trials – standardization of preanalytical conditions
2017 · Lisanne F. van Dessel, Nick Beije, et al. · Molecular Oncology · 162
PDF
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice
2019 · Elena Tirrò, Federica Martorana, et al. · Genes · 101
Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients
2017 · Nick Beije, Anieta M. Sieuwerts, et al. · Molecular Oncology · 60
PDF
Activation of the IGF Axis in Thyroid Cancer: Implications for Tumorigenesis and Treatment
2019 · Livia Manzella, Michele Massimino, et al. · International Journal of Molecular Sciences · 58
PDF
High‐throughput isolation of circulating tumor DNA : a comparison of automated platforms
2018 · Lisanne F. van Dessel, Silvia R. Vitale, et al. · Molecular Oncology · 53
PDF
PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance
2021 · Silvia Rita Vitale, Federica Martorana, et al. · Critical Reviews in Oncology/Hematology · 48
Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma
2021 · Elena Tirrò, Michele Massimino, et al. · Frontiers in Oncology · 44
PDF
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives
2020 · MICHELE MASSIMINO, STEFANIA STELLA, et al. · Anticancer Research · 37
PDF
TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer
2020 · Silvia R. Vitale, Floris H. Groenendijk, et al. · Biomolecules · 37
PDF
Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia
2016 · Livia Manzella, Elena Tirrò, et al. · Current Cancer Drug Targets · 36
Detection of tumor-derived extracellular vesicles in plasma from patients with solid cancer
2021 · Silvia R. Vitale, Jean A. Helmijr, et al. · BMC Cancer · 33
PDF
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53
2019 · Elena Tirrò, Michele Massimino, et al. · Frontiers in Oncology · 31
PDF
Opportunities and Challenges of Liquid Biopsy in Thyroid Cancer
2021 · Chiara Romano, Federica Martorana, et al. · International Journal of Molecular Sciences · 30
PDF
Effect of Combined Epigenetic Treatments and Ectopic NIS Expression on Undifferentiated Thyroid Cancer Cells
2018 · MICHELE MASSIMINO, ELENA TIRRÒ, et al. · Anticancer Research · 24
PDF
The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer
2022 · Silvia R. Vitale, Kirsten Ruigrok-Ritstier, et al. · BMC Cancer · 23
PDF
Molecular Pathogenesis and Treatment Perspectives for Hypereosinophilia and Hypereosinophilic Syndromes
2021 · Stefania Stella, Michele Massimino, et al. · International Journal of Molecular Sciences · 22
PDF
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib
2019 · Stefania Stella, Valentina Zammit, et al. · International Journal of Molecular Sciences · 22
PDF
An Optimized Workflow to Evaluate Estrogen Receptor Gene Mutations in Small Amounts of Cell-Free DNA
2018 · Silvia R. Vitale, Anieta M. Sieuwerts, et al. · Journal of Molecular Diagnostics · 21
Single-Cell Analysis in the Omics Era: Technologies and Applications in Cancer
2023 · Michele Massimino, Federica Martorana, et al. · Genes · 20
PDF
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts
2021 · Michele Massimino, Elena Tirrò, et al. · Frontiers in Pharmacology · 17
PDF
BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors
2019 · Maria Stella Pennisi, Stefania Stella, et al. · Frontiers in Oncology · 17
PDF
Efficacy of Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22)
2019 · ELENA TIRRÒ, MICHELE MASSIMINO, et al. · Anticancer Research · 14
PDF
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report
2019 · MICHELE MASSIMINO, STEFANIA STELLA, et al. · Anticancer Research · 14
PDF
B-ALL Relapses After Autologous Stem Cell Transplantation Associated With a Shift from e1a2 to e14a2 BCR-ABL Transcripts: A Case Report
2018 · STEFANIA STELLA, MICHELE MASSIMINO, et al. · Anticancer Research · 14
PDF
Works count: 59
Citation count: 1,297
H-index: 20
I10-index: 32
Year
Topic
Type